WHO Prequalification

WHO Prequalification (PQ) is the World Health Organization programme that evaluates priority medicines, vaccines, IVDs, vector-control products + APIs against a single harmonised international standard, so that UN procurement agencies + LMIC governments can purchase with confidence. PQ is not itself a marketing authorisation — a manufacturer still needs national marketing authorisations in countries of supply — but in practical procurement reality, PQ listing is the de-facto gateway for the multi-billion-dollar UN + Global Fund + Gavi + GDF (Global Drug Facility) + UNITAID-financed public-health pipeline.

PQ is operated by the Department of Regulation and Prequalification at WHO Geneva. The four product streams are:

• PQ Medicines — finished pharmaceutical products (FPPs) for priority disease areas (HIV, TB, malaria, neglected tropical diseases, reproductive health, hepatitis, COVID-19, paediatric formulations + others).
• PQ Vaccines — vaccines on the EPI schedule + other priority vaccines (oral polio, rotavirus, HPV, meningococcal, pneumococcal, influenza, COVID-19 + others).
• PQ IVDs — in-vitro diagnostics for HIV, hepatitis, malaria, syphilis, TB, COVID-19, HPV + others; assessed against WHO Technical Specifications Series (TSS) per assay type.
• PQ Vector Control Products — long-lasting insecticidal nets (LLINs), indoor residual sprays (IRS), larvicides, space sprays + other vector-control tools.
• PQ APIs — active pharmaceutical ingredients used in PQ FPPs; manufacturers can independently submit an API for PQ, accelerating FPP submissions that reference the PQed API.

Each stream operates on the same broad procedural pattern: WHO publishes an Expression of Interest (EOI) priority list, manufacturers submit a structured dossier, expert assessors review the dossier (often jointly with national regulators), WHO + national regulators inspect the manufacturing site (or rely on a recent inspection by a Stringent Regulatory Authority / WHO-Listed Authority), and on satisfactory completion the product is listed in the WHO Prequalified Products List.

Reliance is central to PQ. WHO has historically used the concept of the Stringent Regulatory Authority (SRA) — regulators of countries that are ICH members + observers + associated members under the pre-ICH-membership-restructure framework, plus EU regulatory architecture — to recognise marketing authorisations + inspections + post-market actions as acceptable equivalents to PQ-led assessment + inspection.

• Historical SRA list — EMA + EU Member State authorities, FDA, MHRA (UK), Health Canada, TGA (Australia), PMDA (Japan), Swissmedic, plus regulators in Iceland, Liechtenstein + Norway.
• PQ Collaborative Procedure — WHO PQ + SRA collaboration whereby an SRA-approved product (e.g. EMA Article 58 / EU-M4all + collaborative review with WHO) can be PQed faster, leveraging the SRA assessment.
• EMA Article 58 + EU-M4all — EMA scientific opinion mechanism for medicines for use exclusively outside the EU, primarily for LMIC public-health priorities; the assessment is performed by CHMP with WHO observer participation + can directly support WHO PQ + LMIC national approvals.
• WHO-Listed Authority (WLA) framework — replacing SRA conceptually + operationally; WHO publishes lists of WLAs at three transitional levels (Transitional WLA-3, Transitional WLA-4 + WLA full) based on the WHO Global Benchmarking Tool (GBT) maturity assessment.
• GBT Maturity Levels — ML1 (some elements present), ML2 (evolving), ML3 (stable, well-functioning, integrated), ML4 (operating at advanced level + continuous improvement). WLA designation typically requires ML3 / ML4 in the relevant function.
• Reliance scope — WHO PQ progressively maps WLA scope to specific functions (marketing authorisation, GMP inspection, pharmacovigilance, lot release for vaccines, clinical-trial oversight, market control) — not blanket recognition but function-by-function.
• Implications for manufacturers — submissions can leverage SRA / WLA approval + inspection outcomes to reduce duplicate work, accelerate PQ listing + de-risk procurement.

• PQ Vaccines — assessment includes National Regulatory Authority (NRA) functionality in the manufacturer's country (the NRA must have demonstrable maturity in vaccine regulation, typically ML3 / ML4 in the WHO GBT for vaccines) + WHO assessment of the manufacturer + manufacturing site + product specification + lot release + post-market.
• Lot release — WHO PQ vaccines typically require lot release by the manufacturer's NRA + WHO sample testing in early years of PQ.
• Vaccine variations + post-PQ — strict change-control + post-PQ surveillance because vaccine procurement (UNICEF + Gavi) operates on long-term forecasts + tendering cycles.
• PQ IVDs — assessment includes a product dossier review against the relevant WHO Technical Specifications Series (TSS) per assay type (e.g. HIV, hepatitis, malaria, syphilis, TB, COVID-19, HPV, NAT) + a WHO performance evaluation at WHO-collaborating laboratories + a QMS audit (or reliance on ISO 13485 from a WHO-recognised certification body) + Site Visit Inspection.
• PQ IVD performance evaluation — independent laboratory testing against WHO panels + sensitivity / specificity / lot-to-lot reproducibility metrics; passage is a gating criterion.
• PQ Vector Control — assessment includes Efficacy (against WHO-published test methods + target species), Safety (toxicology + occupational), Quality (manufacturing + GMP-like principles per WHO Vector Control GMP), Durability + the relevant Pesticide Evaluation Scheme (WHOPES legacy + the current PQ Vector Control architecture under the Pesticide Evaluation Scheme).
• PQ APIs — independent API submission; PQed APIs accelerate FPP submissions that reference the PQed API via API Master File or CEP-equivalent linkage.

• WHO GMP — WHO publishes the Good Manufacturing Practices for Pharmaceutical Products (Main Principles) — Annex 2 of the WHO Technical Report Series, the foundational global GMP text + the spine for PIC/S GMP, EU GMP + most national GMP texts.
• WHO GMP for APIs — substantively equivalent to ICH Q7.
• WHO GMP for Biological Products + Vaccines — separate Annexes covering vaccine-specific + biological-product-specific elements.
• WHO GMP for HVAC + Water + Specific Dosage Forms — published Annexes addressing specific facility + utility + dosage-form considerations.
• WHO PQ Inspectorate — WHO-engaged inspectors (current + former NRA inspectors + WHO-recruited inspectors) conduct PQ inspections, often jointly with national regulators (NRA of the manufacturer + sometimes interested LMIC NRAs).
• Inspection categories — Pre-PQ inspection (first inspection prior to listing), Re-inspection (typically every 3 years), Triggered inspection (in response to quality signals, complaints, recalls, deficiencies), For-cause inspection (specific complaint or signal investigation).
• Public Inspection Report (PIR) — WHO publishes a redacted PIR for every PQ inspection — globally visible + read by every NRA, procurement body + competitor; PIR findings drive significant operational + reputational consequences.
• Reliance — WHO PQ can rely on SRA / WLA inspections (especially EMA + FDA + Health Canada + TGA + PMDA + MHRA + Swissmedic) — reducing the need for a separate PQ inspection on sites with recent satisfactory SRA / WLA inspection.
• Joint inspections — WHO PQ + multiple NRAs frequently conduct joint inspections, reducing duplicate audit burden for the manufacturer + harmonising findings.

• Variations — Change-control submissions to WHO PQ for any change that could affect quality, safety or efficacy; variation classification (Minor / Major) with appropriate review + approval routes.
• Periodic Safety Update Reports (PSURs) — PQ products submit PSURs to WHO PQ on a defined cycle aligned with ICH E2C(R2) substantively.
• Quality Complaints + Recalls — PQ Quality Defects + Recall procedure; recalls coordinated with affected LMIC NRAs + UN procurement agencies; quality-defect signals analysed by WHO PQ for systemic + product-specific implications.
• Post-market quality monitoring — WHO PQ commissions independent quality-monitoring studies (sampling + testing) of products in actual LMIC distribution channels for key disease areas (e.g. anti-malarials, ARVs, paediatric formulations) — findings can drive re-inspection, variation requirements + delisting.
• Re-inspection — typically every 3 years for PQed sites; gap closure is gating for continued PQ status.
• WHOPAR + PIR updates — Public Assessment Reports + Public Inspection Reports are updated as PQ status, variations + inspection outcomes change.
• Pharmacovigilance + adverse-event signals — WHO Programme for International Drug Monitoring (Uppsala Monitoring Centre + WHO VigiBase) operates the global ADR signal-detection infrastructure that interfaces with PQ; safety signals can trigger PQ regulatory action.
• Delisting + Removal — Delisting can be voluntary (manufacturer withdrawal) or involuntary (PQ-initiated for non-compliance); has immediate procurement implications.

• EOI mis-alignment — submission for a product / disease area / dosage form outside the current WHO PQ EOI; submission deprioritised.
• BE study quality issues — bioequivalence studies conducted at non-WHO-recognised BE centres or with documented data-integrity findings.
• API + FPP linkage gaps — finished-product dossier references an API source without an established WHO PQ API or proper linkage documentation.
• Stability data thin — long-term stability data insufficient for the WHO-Zone IVa / IVb climatic conditions typical of LMIC supply.
• QMS gaps revealed at inspection — gaps in deviation, CAPA, change control, complaint handling, batch-record review or data integrity (ALCOA+); PIR publication has global reputational impact.
• Manufacturing-site cleanliness + sterile-products Annex 1 (2022 revision) gaps — particularly sterile-product manufacturers struggling with the revised contamination control strategy + EM expectations.
• API source diversification not documented — single-API source without WHO PQ-acceptable contingency.
• Variation submissions late — change implemented at the manufacturing site without prior WHO PQ approval or post-implementation notification per the variation classification.
• Re-inspection findings unresolved — gaps from previous PQ inspection still open at re-inspection.
• PQ Vaccines — manufacturer NRA functionality gap (the NRA in the manufacturing country has gaps that prevent or delay vaccine PQ).
• PQ IVDs — performance-evaluation failure on WHO panels (sensitivity / specificity / lot-to-lot) — gating failure.
• PQ Vector Control — efficacy data insufficient against target species + insecticide-resistance considerations; durability data thin.
• Post-market quality-monitoring failure — a sampled product fails WHO post-market testing → re-inspection + variation + possible delisting.
• Recall execution inadequate — affected LMIC distribution channels not fully addressed; PQ + national NRA follow-up required.
• WHOPAR / PIR inaccuracies discovered → corrections + reputational implications for the manufacturer.

• Pre-submission meeting count + commitment-incorporation rate before PQ submission.
• PQ submission cycle time (submission → listing) per product.
• Collaborative Registration Procedure (CRP) uptake in LMIC countries of interest.
• Reliance utilisation rate (SRA / WLA approval + inspection leveraged in submission).
• PQ inspection outcome trend (Pre-PQ / Re-inspection / Triggered) + PIR finding count + severity.
• PQ variations on-time submission + approval rate.
• PSUR on-time submission rate.
• Post-market quality-monitoring pass rate per product.
• Recall classification + execution + verification timeline per recall.
• API + BE centre + finished-product site WHO PQ certificate continuity.
• Stability-data adequacy for Zone IVa / IVb climatic conditions.
• Delisting risk indicators (open critical findings, sustained quality signals, NRA functionality gaps).

V5 Ultimate runs the WHO GMP + QMS + pharmacovigilance evidence layer underneath every WHO PQ-regulated activity. Specifically:

• WHO GMP + Annex 11-equivalent control framework — computerised-systems lifecycle, electronic-record + electronic-signature controls, ALCOA+ data-integrity expectations aligned with WHO PQ + SRA / WLA inspector expectations.
• PQ inspection readiness — full document control, training, deviation, CAPA, change control, complaint, recall + post-market surveillance evidence pre-staged for WHO PQ + joint NRA inspector requests, with PIR-publication-grade record traceability.
• PQ dossier packaging — CTD Module 1-5 structure, quality content, BE study packaging, API + excipient master-file linkage + finished-product dossier assembly.
• Reliance + SRA / WLA leverage — cross-walk between EMA / FDA / Health Canada / TGA / PMDA / MHRA approval + inspection outcomes and WHO PQ submission content + inspection-reliance arguments.
• Variation management — Minor / Major variation classification + WHO PQ-specific routing + submission preparation.
• PSUR + post-market — periodic safety update preparation + post-market quality-monitoring response workflows.
• Recall execution — quality-defect + recall classification + LMIC distribution-channel tracking + WHO PQ + national NRA + procurement-agency notification.
• Stability programme — Zone IVa / IVb stability study design + data capture + WHO PQ stability dossier packaging.
• Manufacturing-network management — multi-site PQ status tracking + site-specific PIR + variation tracking + reliance management per site.
• PQ + CRP coordination — Collaborative Registration Procedure participation tracking per LMIC country of interest.
• Audit trail + e-signature — 21 CFR Part 11-equivalent + WHO GMP + PIC/S-aligned record-keeping for WHO + joint NRA inspection use.
• Vaccines + IVDs + Vector Control specifics — stream-specific evidence layers including lot-release, performance evaluation, efficacy + durability data structures aligned with the respective PQ assessment frameworks.